Medicines Co [The] (MDCO) 37.27 $MDCO
The Medicines Company Prices $350 Million of Convertible Notes
BusinessWire - Mon Jun 06, 9:14PM CDT
The Medicines Company (NASDAQ:MDCO) (the "Company"
today announced that it has priced its private offering of $350 million in aggregate principal amount of its convertible senior notes due 2023. The notes will be sold only to qualified institutional buyers pursuant to Rule 144A under the Securities Act of 1933, as amended. The notes will be senior unsecured obligations of the Company and will mature on July 15, 2023, unless earlier converted, redeemed or repurchased in accordance with their terms. The notes will bear interest at a rate of 2.75% per year, payable semi-annually. The notes will be convertible prior to April 15, 2023 only upon the occurrence of certain circumstances and will be convertible thereafter regardless of these circumstances, in either case, into cash, shares of the Company's common stock or a combination thereof, at the Company's option. The conversion rate for the notes will initially be 20.4198 shares of common stock per $1,000 principal amount, which is equivalent to an initial conversion price of approximately $48.97 per share of common stock. The initial conversion price of the notes represents a premium of approximately 32.5% to the $36.96 per share last reported sale price of the Company's common stock on June 6, 2016. The Company has granted to the initial purchasers the option to purchase up to an additional $52.5 million in aggregate principal amount of the notes. The sale of the notes is expected to close on or about June 10, 2016, subject to customary closing conditions.
MDCO: 37.27 (-1.21)
Medicines Co Set to Possibly Pullback After Yesterday's Rally of 2.04%
Comtex SmarTrend(R) - Mon Jun 06, 4:25PM CDT
Medicines Co (NASDAQ:MDCO) traded in a range yesterday that spanned from a low of $36.10 to a high of $38.49. Yesterday, the shares gained 2.0%, which took the trading range above the 3-day high of $38.33 on volume of 1.2 million shares. Often times after large one-day gains, short term traders will seek to take profits and, as such, investors should be cautious.
MDCO: 37.27 (-1.21)
Why Investors Have This Drug Makers' Stocks on Their Radar? - Carbylan Therapeutics, Catalent Inc., Medicines Co., and Diplomat Pharmacy
PR Newswire - Mon Jun 06, 7:00AM CDT
The Generic Drugs space is an attractive yet very competitive industry. In today's lineup, ActiveWallSt.com have these companies: Carbylan Therapeutics Inc. (NASDAQ: CBYL), Catalent Inc. (NYSE: CTLT), The Medicines Co. (NASDAQ: MDCO), and Diplomat Pharmacy Inc. (NYSE: DPLO). Learn more about these stocks and receive your complimentary trade alerts at:
MDCO: 37.27 (-1.21), DPLO: 33.79 (-0.39), CTLT: 23.03 (-0.43), CBYL: 1.19 (-0.05)
The Medicines Company Announces Intention to Offer $350 Million of Convertible Notes
BusinessWire - Mon Jun 06, 5:57AM CDT
The Medicines Company (NASDAQ:MDCO) (the "Company" today announced that it proposes to offer $350 million aggregate principal amount of convertible senior notes due 2023, subject to market conditions and other factors. The notes are to be offered and sold only to qualified institutional buyers pursuant to Rule 144A under the Securities Act of 1933, as amended. The notes will be convertible, upon certain conditions, into cash, shares of the Company's common stock or a combination thereof, at the Company's option. The interest rate, conversion rate, offering price and other terms will be determined by negotiations among the Company and the initial purchasers of the notes. The Company also expects to grant to the initial purchasers an option to purchase up to an additional $52.5 million aggregate principal amount of the notes.
MDCO: 37.27 (-1.21)
The Medicines Company Completes Patient Enrollment for ORION-1 Study of PCSK9si
BusinessWire - Thu Jun 02, 6:00AM CDT
--Randomized 501 patients with high cardiovascular risk and high LDL-C ("bad cholesterol" despite current treatment
MDCO: 37.27 (-1.21)
The Medicines Co. Carbavance TANGO 1 Study Enrolled
Zacks Equity Research - Zacks Investment Research - Fri May 27, 1:45PM CDT
The Medicines Company (MDCO) announced that it has completed enrollment in the phase III TANGO 1 study on Carbavance for the treatment of cUTI.
MDCO: 37.27 (-1.21), ANIP: 52.75 (-0.94), RTRX: 17.72 (+0.02), ACOR: 27.36 (-0.16)
The Medicines Company Announces Completion of Patient Enrollment in Phase 3 TANGO 1 Study of CARBAVANCE(R) (meropenem-vaborbactam) for Treatment of Complicated Urinary Tract Infections (cUTI)
BusinessWire - Thu May 26, 3:31PM CDT
The Medicines Company (NASDAQ:MDCO) has announced the completion of patient enrollment in the Phase 3 TANGO 1 study of CARBAVANCE(R) (meropenem-vaborbactam), an investigational agent being developed for the treatment of complicated urinary tract infections (cUTI). TANGO 1 was initiated in the fourth quarter of 2014 under a cost-share agreement with the Biomedical Advanced Research and Development Authority (BARDA) to support the development of CARBAVANCE. Top-line data are expected in the second half of 2016.
MDCO: 37.27 (-1.21)
The Medicines Company to Present at Two Upcoming Investor Conferences
BusinessWire - Wed May 25, 4:54PM CDT
The Medicines Company (NASDAQ:MDCO) today announced that the company is scheduled to make presentations at the following June investor conferences:
MDCO: 37.27 (-1.21)
The Medicines Company Appoints Tony Kingsley as President and Chief Operating Officer
BusinessWire - Mon May 16, 6:00AM CDT
The Medicines Company (NASDAQ:MDCO) has announced the appointment of Tony Kingsley as President and Chief Operating Officer. Mr. Kingsley will help oversee the day-to-day operations of the company and will lead the company's commercial activities.
MDCO: 37.27 (-1.21), HOLX: 34.40 (-0.55)
The Medicines Co. Loss Wider, to Divest Cardiovascular Drugs
Zacks Equity Research - Zacks Investment Research - Tue May 10, 10:24AM CDT
The Medicines Company (MDCO) reported a wider-than-expected loss of $1.13 per share in the first quarter of 2016.
MNK: 60.70 (-1.83), MDCO: 37.27 (-1.21), ANIP: 52.75 (-0.94), NVS: 79.03 (-1.48)
Medicines Co. reports 1Q loss
Automated Insights - Mon May 09, 6:35AM CDT
PARSIPPANY, N.J. (AP) _ The Medicines Co. (MDCO) on Monday reported a first-quarter loss of $92.4 million, after reporting a profit in the same period a year earlier.
MDCO: 37.27 (-1.21)
The Medicines Company Reports First-Quarter 2016 Business and Financial Results
BusinessWire - Mon May 09, 6:05AM CDT
--The announced divestiture of non-core cardiovascular assets to Chiesi Farmaceutici S.p.A. will sharpen strategic focus and significantly strengthen financial position to drive further development of R&D programs without diluting shareholders
MDCO: 37.27 (-1.21)
The Medicines Company Agrees to Divest Non-Core Cardiovascular Assets to Chiesi Farmaceutici S.p.A.
BusinessWire - Mon May 09, 6:00AM CDT
--Total consideration of up to $792 million and anticipated reduction in annual SG&A and related R&D expenses of between $65 million and $80 million
MDCO: 37.27 (-1.21)
Biotech Stocks Reporting on May 9: INCY, HZNP, JUNO & More
Kanchan Khanna - Zacks Investment Research - Fri May 06, 8:52AM CDT
What's in store for biotech stocks Juno, Incyte and others when they report their first-quarter results on May 9?
HALO: 8.80 (-0.17), KITE: 51.87 (-1.55), MDCO: 37.27 (-1.21), INCY: 81.22 (-0.39), HZNP: 18.15 (-0.38), AMGN: 154.85 (-1.93), JUNO: 44.01 (-1.52)
Alnylam Pharmaceuticals, Inc.'s Double-Digit "Earnings" Fall
Brian Orelli, The Motley Fool - Motley Fool - Wed May 04, 1:12PM CDT
What: Alnylam Pharmaceuticals released earnings on Monday after the bell and fell 11.6% on Tuesday. Of course, without any products on the market, the biotech's earnings don't really matter. But for the record, Alnylam recorded $7.3 million in...
ALNY: 63.31 (-2.10), MDCO: 37.27 (-1.21), ALXN: 136.06 (-2.18)
Mallinckrodt (MNK) Tops Q2 Earnings and Sales, Ups View
Zacks Equity Research - Zacks Investment Research - Tue May 03, 9:49AM CDT
Mallinckrodt (MNK) reported adjusted earnings of $2.01 per share in the second quarter of fiscal 2016 (ended Mar 25, 2016), beating the Zacks Consensus Estimate of $1.72.
MNK: 60.70 (-1.83), GILD: 84.70 (-1.07), MDCO: 37.27 (-1.21), AEGR: 1.42 (-0.08)
The Medicines Company to Present at Bank of America Merrill Lynch 2016 Health Care Conference
BusinessWire - Mon May 02, 7:32AM CDT
The Medicines Company (NASDAQ:MDCO) is scheduled to present at the Bank of America Merrill Lynch 2016 Health Care Conference in Las Vegas, NV on Tuesday, May 10, 2016, at 8:00 AM PT (11:00 AM ET).
MDCO: 37.27 (-1.21)
The Medicines Company to Announce First Quarter Financial Results on May 9, 2016
BusinessWire - Tue Apr 26, 7:49AM CDT
The Medicines Company (NASDAQ:MDCO) has scheduled its quarterly conference call forMay 9th at 8:30 a.m. Eastern Time to discuss first quarter financial results and operational developments.
MDCO: 37.27 (-1.21)
FDA Grants Fast Track Status for Investigational Antibiotic CARBAVANCE(R) (meropenem-vaborbactam)
BusinessWire - Mon Apr 11, 6:00AM CDT
The Medicines Company (NASDAQ:MDCO) today announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track Designation to the investigational agent CARBAVANCE(R) (meropenem-vaborbactam) for the treatment of complicated urinary tract infections (cUTI). CARBAVANCE is the combination of the carbapenem antibiotic, meropenem, with the novel beta-lactamase inhibitor, vaborbactam (formerly known as RPX7009), that is being developed for the treatment of gram-negative infections, including those due to carbapenem-resistant Enterobacteriaceae (CRE).
MDCO: 37.27 (-1.21)
The Medicines Company Announces Participation at 2016 European Congress of Clinical Microbiology and Infectious Diseases (ECCMID) to be held April 9-12 in Amsterdam
BusinessWire - Mon Apr 04, 3:30PM CDT
The Medicines Company (NASDAQ:MDCO) today announced that investigators will present data for the Phase 3 investigational agent CARBAVANCE(R) (meropenem-vaborbactam) on activity against newly discovered BKC-1 and FR-1 serine lactamases at the 26th Annual European Congress of Clinical Microbiology and Infectious Diseases (ECCMID), held April 9-12 in Amsterdam. Investigators will also present data for ORBACTIV(R) (oritavancin) activity tested against European staphylococcal clinical isolates, including those with reduced susceptibility to daptomycin, teicoplanin or vancomycin.
MDCO: 37.27 (-1.21)
The Medicines Company Prices $350 Million of Convertible Notes
BusinessWire - Mon Jun 06, 9:14PM CDT
The Medicines Company (NASDAQ:MDCO) (the "Company"
today announced that it has priced its private offering of $350 million in aggregate principal amount of its convertible senior notes due 2023. The notes will be sold only to qualified institutional buyers pursuant to Rule 144A under the Securities Act of 1933, as amended. The notes will be senior unsecured obligations of the Company and will mature on July 15, 2023, unless earlier converted, redeemed or repurchased in accordance with their terms. The notes will bear interest at a rate of 2.75% per year, payable semi-annually. The notes will be convertible prior to April 15, 2023 only upon the occurrence of certain circumstances and will be convertible thereafter regardless of these circumstances, in either case, into cash, shares of the Company's common stock or a combination thereof, at the Company's option. The conversion rate for the notes will initially be 20.4198 shares of common stock per $1,000 principal amount, which is equivalent to an initial conversion price of approximately $48.97 per share of common stock. The initial conversion price of the notes represents a premium of approximately 32.5% to the $36.96 per share last reported sale price of the Company's common stock on June 6, 2016. The Company has granted to the initial purchasers the option to purchase up to an additional $52.5 million in aggregate principal amount of the notes. The sale of the notes is expected to close on or about June 10, 2016, subject to customary closing conditions. MDCO: 37.27 (-1.21)
Medicines Co Set to Possibly Pullback After Yesterday's Rally of 2.04%
Comtex SmarTrend(R) - Mon Jun 06, 4:25PM CDT
Medicines Co (NASDAQ:MDCO) traded in a range yesterday that spanned from a low of $36.10 to a high of $38.49. Yesterday, the shares gained 2.0%, which took the trading range above the 3-day high of $38.33 on volume of 1.2 million shares. Often times after large one-day gains, short term traders will seek to take profits and, as such, investors should be cautious.
MDCO: 37.27 (-1.21)
Why Investors Have This Drug Makers' Stocks on Their Radar? - Carbylan Therapeutics, Catalent Inc., Medicines Co., and Diplomat Pharmacy
PR Newswire - Mon Jun 06, 7:00AM CDT
The Generic Drugs space is an attractive yet very competitive industry. In today's lineup, ActiveWallSt.com have these companies: Carbylan Therapeutics Inc. (NASDAQ: CBYL), Catalent Inc. (NYSE: CTLT), The Medicines Co. (NASDAQ: MDCO), and Diplomat Pharmacy Inc. (NYSE: DPLO). Learn more about these stocks and receive your complimentary trade alerts at:
MDCO: 37.27 (-1.21), DPLO: 33.79 (-0.39), CTLT: 23.03 (-0.43), CBYL: 1.19 (-0.05)
The Medicines Company Announces Intention to Offer $350 Million of Convertible Notes
BusinessWire - Mon Jun 06, 5:57AM CDT
The Medicines Company (NASDAQ:MDCO) (the "Company"
today announced that it proposes to offer $350 million aggregate principal amount of convertible senior notes due 2023, subject to market conditions and other factors. The notes are to be offered and sold only to qualified institutional buyers pursuant to Rule 144A under the Securities Act of 1933, as amended. The notes will be convertible, upon certain conditions, into cash, shares of the Company's common stock or a combination thereof, at the Company's option. The interest rate, conversion rate, offering price and other terms will be determined by negotiations among the Company and the initial purchasers of the notes. The Company also expects to grant to the initial purchasers an option to purchase up to an additional $52.5 million aggregate principal amount of the notes. MDCO: 37.27 (-1.21)
The Medicines Company Completes Patient Enrollment for ORION-1 Study of PCSK9si
BusinessWire - Thu Jun 02, 6:00AM CDT
--Randomized 501 patients with high cardiovascular risk and high LDL-C ("bad cholesterol"
despite current treatment MDCO: 37.27 (-1.21)
The Medicines Co. Carbavance TANGO 1 Study Enrolled
Zacks Equity Research - Zacks Investment Research - Fri May 27, 1:45PM CDT
The Medicines Company (MDCO) announced that it has completed enrollment in the phase III TANGO 1 study on Carbavance for the treatment of cUTI.
MDCO: 37.27 (-1.21), ANIP: 52.75 (-0.94), RTRX: 17.72 (+0.02), ACOR: 27.36 (-0.16)
The Medicines Company Announces Completion of Patient Enrollment in Phase 3 TANGO 1 Study of CARBAVANCE(R) (meropenem-vaborbactam) for Treatment of Complicated Urinary Tract Infections (cUTI)
BusinessWire - Thu May 26, 3:31PM CDT
The Medicines Company (NASDAQ:MDCO) has announced the completion of patient enrollment in the Phase 3 TANGO 1 study of CARBAVANCE(R) (meropenem-vaborbactam), an investigational agent being developed for the treatment of complicated urinary tract infections (cUTI). TANGO 1 was initiated in the fourth quarter of 2014 under a cost-share agreement with the Biomedical Advanced Research and Development Authority (BARDA) to support the development of CARBAVANCE. Top-line data are expected in the second half of 2016.
MDCO: 37.27 (-1.21)
The Medicines Company to Present at Two Upcoming Investor Conferences
BusinessWire - Wed May 25, 4:54PM CDT
The Medicines Company (NASDAQ:MDCO) today announced that the company is scheduled to make presentations at the following June investor conferences:
MDCO: 37.27 (-1.21)
The Medicines Company Appoints Tony Kingsley as President and Chief Operating Officer
BusinessWire - Mon May 16, 6:00AM CDT
The Medicines Company (NASDAQ:MDCO) has announced the appointment of Tony Kingsley as President and Chief Operating Officer. Mr. Kingsley will help oversee the day-to-day operations of the company and will lead the company's commercial activities.
MDCO: 37.27 (-1.21), HOLX: 34.40 (-0.55)
The Medicines Co. Loss Wider, to Divest Cardiovascular Drugs
Zacks Equity Research - Zacks Investment Research - Tue May 10, 10:24AM CDT
The Medicines Company (MDCO) reported a wider-than-expected loss of $1.13 per share in the first quarter of 2016.
MNK: 60.70 (-1.83), MDCO: 37.27 (-1.21), ANIP: 52.75 (-0.94), NVS: 79.03 (-1.48)
Medicines Co. reports 1Q loss
Automated Insights - Mon May 09, 6:35AM CDT
PARSIPPANY, N.J. (AP) _ The Medicines Co. (MDCO) on Monday reported a first-quarter loss of $92.4 million, after reporting a profit in the same period a year earlier.
MDCO: 37.27 (-1.21)
The Medicines Company Reports First-Quarter 2016 Business and Financial Results
BusinessWire - Mon May 09, 6:05AM CDT
--The announced divestiture of non-core cardiovascular assets to Chiesi Farmaceutici S.p.A. will sharpen strategic focus and significantly strengthen financial position to drive further development of R&D programs without diluting shareholders
MDCO: 37.27 (-1.21)
The Medicines Company Agrees to Divest Non-Core Cardiovascular Assets to Chiesi Farmaceutici S.p.A.
BusinessWire - Mon May 09, 6:00AM CDT
--Total consideration of up to $792 million and anticipated reduction in annual SG&A and related R&D expenses of between $65 million and $80 million
MDCO: 37.27 (-1.21)
Biotech Stocks Reporting on May 9: INCY, HZNP, JUNO & More
Kanchan Khanna - Zacks Investment Research - Fri May 06, 8:52AM CDT
What's in store for biotech stocks Juno, Incyte and others when they report their first-quarter results on May 9?
HALO: 8.80 (-0.17), KITE: 51.87 (-1.55), MDCO: 37.27 (-1.21), INCY: 81.22 (-0.39), HZNP: 18.15 (-0.38), AMGN: 154.85 (-1.93), JUNO: 44.01 (-1.52)
Alnylam Pharmaceuticals, Inc.'s Double-Digit "Earnings" Fall
Brian Orelli, The Motley Fool - Motley Fool - Wed May 04, 1:12PM CDT
What: Alnylam Pharmaceuticals released earnings on Monday after the bell and fell 11.6% on Tuesday. Of course, without any products on the market, the biotech's earnings don't really matter. But for the record, Alnylam recorded $7.3 million in...
ALNY: 63.31 (-2.10), MDCO: 37.27 (-1.21), ALXN: 136.06 (-2.18)
Mallinckrodt (MNK) Tops Q2 Earnings and Sales, Ups View
Zacks Equity Research - Zacks Investment Research - Tue May 03, 9:49AM CDT
Mallinckrodt (MNK) reported adjusted earnings of $2.01 per share in the second quarter of fiscal 2016 (ended Mar 25, 2016), beating the Zacks Consensus Estimate of $1.72.
MNK: 60.70 (-1.83), GILD: 84.70 (-1.07), MDCO: 37.27 (-1.21), AEGR: 1.42 (-0.08)
The Medicines Company to Present at Bank of America Merrill Lynch 2016 Health Care Conference
BusinessWire - Mon May 02, 7:32AM CDT
The Medicines Company (NASDAQ:MDCO) is scheduled to present at the Bank of America Merrill Lynch 2016 Health Care Conference in Las Vegas, NV on Tuesday, May 10, 2016, at 8:00 AM PT (11:00 AM ET).
MDCO: 37.27 (-1.21)
The Medicines Company to Announce First Quarter Financial Results on May 9, 2016
BusinessWire - Tue Apr 26, 7:49AM CDT
The Medicines Company (NASDAQ:MDCO) has scheduled its quarterly conference call forMay 9th at 8:30 a.m. Eastern Time to discuss first quarter financial results and operational developments.
MDCO: 37.27 (-1.21)
FDA Grants Fast Track Status for Investigational Antibiotic CARBAVANCE(R) (meropenem-vaborbactam)
BusinessWire - Mon Apr 11, 6:00AM CDT
The Medicines Company (NASDAQ:MDCO) today announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track Designation to the investigational agent CARBAVANCE(R) (meropenem-vaborbactam) for the treatment of complicated urinary tract infections (cUTI). CARBAVANCE is the combination of the carbapenem antibiotic, meropenem, with the novel beta-lactamase inhibitor, vaborbactam (formerly known as RPX7009), that is being developed for the treatment of gram-negative infections, including those due to carbapenem-resistant Enterobacteriaceae (CRE).
MDCO: 37.27 (-1.21)
The Medicines Company Announces Participation at 2016 European Congress of Clinical Microbiology and Infectious Diseases (ECCMID) to be held April 9-12 in Amsterdam
BusinessWire - Mon Apr 04, 3:30PM CDT
The Medicines Company (NASDAQ:MDCO) today announced that investigators will present data for the Phase 3 investigational agent CARBAVANCE(R) (meropenem-vaborbactam) on activity against newly discovered BKC-1 and FR-1 serine lactamases at the 26th Annual European Congress of Clinical Microbiology and Infectious Diseases (ECCMID), held April 9-12 in Amsterdam. Investigators will also present data for ORBACTIV(R) (oritavancin) activity tested against European staphylococcal clinical isolates, including those with reduced susceptibility to daptomycin, teicoplanin or vancomycin.
MDCO: 37.27 (-1.21)
